Accelerate Diagnostics Inc

Accelerate Diagnostics — 39th Annual J.P. Morgan Healthcare Conference 2021

27 slides from Accelerate Diagnostics's conference presentation, Jan 13, 2021

  1. Slide 1: 39th Annual J.P. Morgan Healthcare Conference

    Slide 1: 39th Annual J.P. Morgan Healthcare Conference

    Jack Phillips President & CEO Accelerate Diagnostics, Inc January 2021 39 TH ANNUAL J.P. Morgan Healthcare Conference

  2. Slide 2: Cautionary Note On Forward-Looking Statements

    Slide 2: Cautionary Note On Forward-Looking Statements

    2 Cautionary Note On Forward - Looking Statements © Copyright 2021 Accelerate Diagnostics, Inc. All Rights Reserved. The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc. All other t

  3. Slide 3: Purpose and Mission

    Slide 3: Purpose and Mission

    PURPOSE We deliver lifesaving answers for patients with serious infections MISSION Expand our market leadership in Rapid ID/AST by delivering innovation with clear clinical and financial value for health systems and patients 3

  4. Slide 4: Sepsis is the most significant cost and source of mortality in U.S. hospitals

    Slide 4: Sepsis is the most significant cost and source of mortality in U.S. hospitals

    270,000 deaths in the U.S. annually 2 Sepsis is the most significant cost and source of mortality in U.S. hospitals 1. U.S. Department of Health and Human Services study: Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012 - 2018 (Ma rch 2020) 2. Centers for Disease Control and Preve

  5. Slide 5: The high cost of sepsis is worsening due in part to rising antimicrobial resistance

    Slide 5: The high cost of sepsis is worsening due in part to rising antimicrobial resistance

    The high cost of sepsis is worsening due in part to rising antimicrobial resistance 1 in 3 1. NIH study by Burnham et al. https:// dx.doi.org /10.1017/ice.2018.304 2. U.S. Department of Health and Human Services study: Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012 - 2018 (Ma rc

  6. Slide 6: COVID is exacerbating the problem

    Slide 6: COVID is exacerbating the problem

    COVID - 19 is exacerbating the problem 72% of COVID - 19 patients received antibiotics when not clinically indicated 1 Langford BJ, So M, Raybardhan S, et al. Bacterial co - infection and secondary infection in patients with COVID - 19: a living rapid review and meta - analysis. Clin Microbiol Infec

  7. Slide 7: Most of the costs of sepsis are avoidable

    Slide 7: Most of the costs of sepsis are avoidable

    Most of the costs of sepsis are avoidable 80% of sepsis deaths could be prevented with rapid diagnosis and treatment 7.6% decrease in chance of survival per hour of delay of effective therapy Kumar A, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical

  8. Slide 8: Conventional methods are too slow to affect the change needed

    Slide 8: Conventional methods are too slow to affect the change needed

    Conventional methods are too slow to affect the change needed for hospitals and patients Based on studies by Accelerate Pheno ® system customers. 8

  9. Slide 9: Our solution is the Accelerate Pheno system

    Slide 9: Our solution is the Accelerate Pheno system

    Our solution is the Accelerate Pheno ® system Fast, actionable results faster time to optimal therapy Based on studies by Accelerate Pheno ® system customers. 9

  10. Slide 10: The Accelerate Pheno delivers proven system-wide clinical and economic benefits

    Slide 10: The Accelerate Pheno delivers proven system-wide clinical and economic benefits

    Cost Savings $1,000 – 3,100 per patient Shorter Length of Stay 2 days Mortality Reduction 8 % Shorter Time to Optimal Therapy 1.1 – 2.2 days Reduced ABX Usage 2 days on therapy Based on studies by Accelerate Pheno ® system customers. The Accelerate Pheno delivers proven system - wide clinical and ec

  11. Slide 11: First mover advantage in highest-acuity segment of substantial IVD market

    Slide 11: First mover advantage in highest-acuity segment of substantial IVD market

    ID/AST restated market value 1 $3.7B ID/AST tests per annum 2 All Other Micro Samples 2 Blood Resp. >100M tests North America EMEA APAC 3 Total Blood: 2.3 1.9 3.3 7.5 Respiratory: 0.9 0.9 0.7 2.5 All Other Micro Samples : 2 38.5 31.8 54.9 125.3 Total: 41.8 34.6 58.9 135.3 (in MM) 1. Approximate figu

  12. Slide 12: Continuing to grow number of live customers in our principal U.S. market

    Slide 12: Continuing to grow number of live customers in our principal U.S. market

    7 54 164 268 Dec-17 Dec-18 Dec-19 Dec-20 1. Contracted Pheno placements by geography: North America: 419, EMEA: 165; Preliminary unaudited 2. Preliminary unaudited 268 Live Phenos , with Backlog of >125 +63% Year - over - year growth in revenue - generating installed base 2 12 Continuing to grow num

  13. Slide 13: Delivered top-line growth and strengthened balance sheet exiting 2020

    Slide 13: Delivered top-line growth and strengthened balance sheet exiting 2020

    1. Preliminary unaudited financial results 2. “Includes $32M raised through a recent equity purchase by certain insiders, which is subject to customary closing conditions Revenue: Gross Margin: Net Cash Burn: Cash Balance: +54% U.S. revenue growth over prior year $11.2M ~ 40% $41M ~ $100M 2 13 Deliv

  14. Slide 14: Three-year plan to grow Pheno market share and expand available market

    Slide 14: Three-year plan to grow Pheno market share and expand available market

    Optimize the selling, implementation, and robustness of Pheno offering Expand the available market through new geographies, partnerships, and Pheno 2.0 3 - year plan to significantly grow Pheno market share and expand available market with Pheno 2.0 Accelerate the Pheno opportunity through PhenoAST

  15. Slide 15: Optimize the selling, implementation, and robustness of Pheno offering

    Slide 15: Optimize the selling, implementation, and robustness of Pheno offering

    Optimize the selling, implementation, and robustness of Pheno offering 15

  16. Slide 16: Optimizing the sales process

    Slide 16: Optimizing the sales process

    Optimizing the sales process Leverage growing & dedicated customer base for aggressive share capture: Referral & regional strategy expansions Improving access to new opportunities Increasing focus on secondary infections, bed utilization, and antimicrobial resistance due to COVID 44% conversion of c

  17. Slide 17: Optimizing implementation process and product robustness

    Slide 17: Optimizing implementation process and product robustness

    164 197 201 223 268 Dec-19 Mar-20 Jun-20 Sep-20 Dec-20 17 Implementation Process Process overhaul showing strong results 100% forecast accuracy for Q4 Trending toward target of 6 - 9mo average time to go - live Product Robustness Continued focused on customer experience with Pheno Continued ID & AST

  18. Slide 18: Accelerate the Pheno opportunity through PhenoAST and PhenoPrep product extensions

    Slide 18: Accelerate the Pheno opportunity through PhenoAST and PhenoPrep product extensions

    Accelerate The Pheno opportunity through Accelerate PhenoAST ™ and Accelerate PhenoPrep® product extensions 18

  19. Slide 19: Accelerating market penetration through Pheno product extensions

    Slide 19: Accelerating market penetration through Pheno product extensions

    Accelerating market penetration through Pheno product extensions MARKET SHARE TIME PhenoTest BC Kit Extensions PhenoAST (AST - only test on Pheno) PhenoPrep (automated MALDI workflow) 19

  20. Slide 20: Accelerating market penetration through launches of PhenoAST and PhenoPrep

    Slide 20: Accelerating market penetration through launches of PhenoAST and PhenoPrep

    Accelerating market penetration through launches of PhenoAST and PhenoPrep product extensions PhenoPrep Existing MALDI PhenoAST Conventional Customer (Slow ID&AST) Fast ID Customer (Rapid ID & Slow AST) MALDI ID Customer (Slow or Rapid MALDI ID & Slow AST) ID/AST Workflow Today Rapid Pheno Workflows

  21. Slide 21: Expand the available market through new geographies, partnerships, and Pheno 2.0

    Slide 21: Expand the available market through new geographies, partnerships, and Pheno 2.0

    Expand the available market through new geographies, partnerships, and Pheno 2.0 21

  22. Slide 22: Continuing Geographic Expansion

    Slide 22: Continuing Geographic Expansion

    Continuing Geographic Expansion China clinical trials continue • Continue Type Testing and clinical trial preparations • Secured first clinical customer in Hong Kong • Continue to build regional KOL network 22 EMEA restructuring complete • Focused approach in Southern Europe and the Middle East • Im

  23. Slide 23: Synergistic Partnerships

    Slide 23: Synergistic Partnerships

    Synergistic Partnerships DIAGNOSTIC STEWARDSHIP ANTIBIOTIC STEWARDSHIP Clinical Patient Evaluation Testing for Infection Source & Type Adjust & Optimize Therapy Early Detection Detection & Culture ID/AST Host Response Ascend MALDI Partnership Other synergistic partnerships across the sepsis manageme

  24. Slide 24: Pheno 2.0, a step-function innovation in rapid AST

    Slide 24: Pheno 2.0, a step-function innovation in rapid AST

    Pheno 2.0, a step - function innovation in rapid AST 24 Current prototype puts Pheno 2.0 on track to be: = $ $ Equivalent accuracy & MICs across broad drug panel 1/10 instrument size & cost Accurate Higher Throughput Lower Cost 1/10 consumable cost < Multi - sample Capable Pheno Pheno 2.0 Enabling i

  25. Slide 25: 2021 Expectations

    Slide 25: 2021 Expectations

    Optimize Significantly more new customers contracted Go - Live cycle approaching 9 months Product optimizations delivered Expand Achieve Pheno 2.0 milestone Deliver revenue - generating partnership Complete first phase of China registration process COVID - 19 continues to impact hospital access, the

  26. Slide 26: 3-Year Market Expansion Expectations

    Slide 26: 3-Year Market Expansion Expectations

    3 - Year Market Expansion Expectations Market share growth and innovation significantly expand available market 1 $1B Pheno + Product Extensions Addressable Market >$3B Market expansion with Pheno 2.0 launch & entry into Chinese market ▪ Long - term gross margin target of ~70% ▪ Strategic importance

  27. Slide 27: Summary

    Slide 27: Summary

    Summary WHO WE ARE A diagnostics company based in Arizona, founded in 2012, with the purpose of delivering lifesaving answers for patients with serious infections. THE PROBLEM Due to the overuse of antibiotics, the human and hospital costs of treating conditions like sepsis are increasing. Each year

Source: SEC EDGAR · 8-K filed Jan 13, 2021

More decks from Accelerate Diagnostics Inc